Dr. Tabernero on Molecular Characterization in GI Cancer
Josep Tabernero, MD, PhD, of Vall d’Hebron University Hospital, Barcelona, believes that in order to treat patients with gastrointestinal cancers more effectively, researchers must focus on the molecular classification of particular subpopulations.
Defining unique subtypes within broad tumor classes will help researchers discover key underlying molecular drivers, Tabernero states. Once discovered, these molecular classifications will aid the development of focused targeted agents for patients with advanced malignancies.
Initially, Tabernero believes, the application of these unique molecular characterizations, gene profiles, and expressed proteins will apply mostly to advanced disease. However, they will be translated into earlier stages through the introduction of new treatment options. These targeted treatment approaches, Tabernero states, will result in better treatment outcomes than conventional therapies.